Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis.
about
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)Complementary and Alternative Therapies in Amyotrophic Lateral SclerosisPhosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis.MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis.One universal common endpoint in mouse models of amyotrophic lateral sclerosis.Epigallocatechin-3-gallate ameliorates hyperglycemia-induced embryonic vasculopathy and malformation by inhibition of Foxo3a activation.S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosisCan consuming flavonoids restore old microglia to their youthful state?Voltage-Gated Proton Channels as Novel Drug Targets: From NADPH Oxidase Regulation to Sperm BiologyRecent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical applicationQuercitrin and quercetin 3-β-d-glucoside as chemical chaperones for the A4V SOD1 ALS-causing mutant.Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Pathway Analysis Revealed Potential Diverse Health Impacts of Flavonoids that Bind Estrogen Receptors.Dual roles of NF-kappaB in cell survival and implications of NF-kappaB inhibitors in neuroprotective therapy.Inflammaging as a prodrome to Alzheimer's diseaseNutrition and dietary supplements in motor neuron disease.Chronic intermittent hypoxia impairs heart rate responses to AMPA and NMDA and induces loss of glutamate receptor neurons in nucleus ambiguous of F344 rats.SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegenerationNeuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties.NitroDIGE analysis reveals inhibition of protein S-nitrosylation by epigallocatechin gallates in lipopolysaccharide-stimulated microglial cells.Nutraceutical antioxidants as novel neuroprotective agents.Iron chelation and neuroprotection in neurodegenerative diseases.Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease.NF-κB signaling pathways: role in nervous system physiology and pathology.A review of experimental research on herbal compounds in amyotrophic lateral sclerosis.Flavonoid-based therapies in the early management of neurodegenerative diseases.Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches.Epigallocatechin-3-gallate protects motor neurons and regulates glutamate level.Protective effects of a green tea polyphenol, epigallocatechin-3-gallate, against sevoflurane-induced neuronal apoptosis involve regulation of CREB/BDNF/TrkB and PI3K/Akt/mTOR signalling pathways in neonatal mice.Peroxynitrite Activates the NLRP3 Inflammasome Cascade in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.A Metadata Analysis of Oxidative Stress Etiology in Preclinical Amyotrophic Lateral Sclerosis: Benefits of Antioxidant Therapy.Epigallocatechin-3-gallate and related phenol compounds redirect the amyloidogenic aggregation pathway of ataxin-3 towards non-toxic aggregates and prevent toxicity in neural cells and Caenorhabditis elegans animal model.A review: inflammatory process in Alzheimer's disease, role of cytokines.
P2860
Q26748605-56BC70B8-E75E-45A0-A91D-5C897B6C3F13Q26777929-97C6BEBB-77EA-42EC-9A52-947A2719E001Q33791649-6D7CB08C-C868-441C-81F4-A219C1D0AC87Q33878853-D0CE1EA6-A19D-4DB2-BC70-D8C63D541816Q33936763-A45F9CCC-9769-4E5E-BD93-63904933B03FQ33976739-585D230B-489F-4001-B312-2FB95BC553A2Q34680962-2DD42EBE-47F9-4C34-B55B-1B697600CA21Q34683712-44E681D9-7320-4B40-8655-25BF5B753FADQ35977268-3533A0DF-6F5B-41BD-9312-5AFA0B8B91FEQ36117618-BECCD455-5933-4137-8720-51E1C6F2CCEAQ36364363-DD31247A-B92F-416F-A78B-3E0CB9BAA1F7Q36648907-94C5E4BE-B867-4C62-8873-BA1D2E44C76AQ36841629-E5F7CDDB-91F5-4040-9296-07730733D44EQ37010500-D8F07245-91C6-4AE9-AEB6-A2BC0BAE7A94Q37041389-CBFBD727-B0ED-46E5-875A-5E40D81FB4ABQ37073851-5035C0EF-99A3-48E7-B6AB-10FA6A0DA994Q37100466-50BE8C17-579E-4E97-BCD5-9D1AD768D2ECQ37101247-F88A67F6-3BFD-4871-892A-2B308FE32926Q37418049-5F033267-3715-488D-B259-67D79D6B19E4Q37579814-0994E7BC-6DDE-4C9B-90CE-B0EF4C332F8FQ37808095-69E2B439-90C5-46BA-85AC-6D26A02EC746Q37821331-92F16C5E-8665-4775-A0AE-8C70027A6D37Q37880104-20A13FD1-7858-452E-BC8E-5D3348C64A17Q38025541-8E6C61FD-BB19-4C60-B570-98BB9F2CFD04Q38092021-C7522CF5-587E-4029-A7CE-FADA80516367Q38320199-D9B96C14-A2B0-44C6-AE1C-5A5CF4FA8F4DQ38925121-6DEE7426-CBD7-49D2-87A6-ADA4D069BD88Q41107984-807FBACF-B134-48D8-910F-B9C7481D3953Q43058247-58F3CBE5-F184-48F5-8531-9F4433AFA9E3Q47982699-6F255E24-4E12-4580-AFD7-7667493FF8F8Q48345753-E9DB8173-5ECD-4096-9942-E3961DE086ACQ49633688-17CF8F8D-BA3D-46E7-B2F8-41EBB1201D2DQ50575490-CF1D2A19-31E3-4308-B723-6320FCB3A4A9Q53328528-1780F4C0-0F8D-4E96-9762-B71AADE55649
P2860
Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Neuroprotective effects of (-) ...... amyotrophic lateral sclerosis.
@en
type
label
Neuroprotective effects of (-) ...... amyotrophic lateral sclerosis.
@en
prefLabel
Neuroprotective effects of (-) ...... amyotrophic lateral sclerosis.
@en
P2093
P1476
Neuroprotective effects of (-) ...... amyotrophic lateral sclerosis.
@en
P2093
P2888
P304
P356
10.1007/S11064-006-9166-Z
P577
2006-10-05T00:00:00Z